Over-the-counter Acamol Focus is based on Excedrin Migraine.
Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA; TASE: TEVA) is investing NIS 1.5 million in the launch of Acamol Focus for the treatment of migraines.
Over-the-counter Acamol Focus is based on Excedrin Migraine, the most widely sold drug in the US for migraines. Teva said that 16% of Israelis suffer from migraines.
Published by Globes [online], Israel business news - www.globes.co.il - on April 29, 2007
© Copyright of Globes Publisher Itonut (1983) Ltd. 2007